Cargando…

Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry

The proliferation marker Ki-67 is one of the most controversially discussed parameters for treatment decisions in breast cancer patients. The purpose of this study was to evaluate the routine use and value of Ki-67 as a prognostic marker, and to analyze the associations between Ki-67 and common hist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inwald, E. C., Klinkhammer-Schalke, M., Hofstädter, F., Zeman, F., Koller, M., Gerstenhauer, M., Ortmann, O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2013
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669503/ https://www.ncbi.nlm.nih.gov/pubmed/23674192 http://dx.doi.org/10.1007/s10549-013-2560-8

Ejemplares similares

4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival
por: Inwald, Elisabeth Christine, et al.
Publicado: (2015)

Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry
por: Inwald, E. C., et al.
Publicado: (2014)

Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology
por: Inwald, EC, et al.
Publicado: (2017)

Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry
por: Inwald, E. C., et al.
Publicado: (2015)

Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score
por: Robertson, Stephanie, et al.
Publicado: (2020)

Long-term improvement of quality of life in patients with breast cancer: supporting patient-physician communication by an electronic tool for inpatient and outpatient care
por: Lindberg-Scharf, Patricia, et al.
Publicado: (2021)

Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients
por: Taubenhansl, Clara, et al.
Publicado: (2019)

Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up
por: Bustreo, Sara, et al.
Publicado: (2016)

Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes
por: Viale, Giuseppe, et al.
Publicado: (2019)

Implementing a system of quality-of-life diagnosis and therapy for breast cancer patients: results of an exploratory trial as a prerequisite for a subsequent RCT
por: Klinkhammer-Schalke, M, et al.
Publicado: (2008)

Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer
por: Klinkhammer-Schalke, M, et al.
Publicado: (2012)

Direct improvement of quality of life in colorectal cancer patients using a tailored pathway with quality of life diagnosis and therapy (DIQOL): study protocol for a randomised controlled trial
por: Klinkhammer-Schalke, Monika, et al.
Publicado: (2015)

Ki67 expression in breast cancer: Correlation with prognostic markers and clinicopathological parameters in Saudi patients
por: Elkablawy, Mohamed A., et al.
Publicado: (2016)

Breast cancer survivors’ recollection of their illness and therapy seven years after enrolment into a randomised controlled clinical trial
por: Lindberg, Patricia, et al.
Publicado: (2015)

Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters
por: Hashmi, Atif Ali, et al.
Publicado: (2019)

Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer
por: Davey, Matthew G., et al.
Publicado: (2021)

Auswirkungen der COVID-19-Pandemie auf die Inzidenz und Therapie von Krebserkrankungen
por: Inwald, Elisabeth C., et al.
Publicado: (2022)

Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index
por: Al-Keilani, Maha S., et al.
Publicado: (2021)

Prognostic value of Ki-67 immunolabelling in primary operable breast cancer.
por: Railo, M., et al.
Publicado: (1993)

Ki-67 as a prognostic marker according to breast cancer molecular subtype
por: Soliman, Nahed A., et al.
Publicado: (2016)

The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease
por: Brockhoff, Gero, et al.
Publicado: (2017)

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
por: Nielsen, Torsten O, et al.
Publicado: (2020)

Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer()()()
por: Surov, Alexey, et al.
Publicado: (2018)

Incidence of Anaplastic Large Cell Lymphoma and Breast-Implant-Associated Lymphoma—An Analysis of a Certified Tumor Registry over 17 Years
por: Prantl, Lukas, et al.
Publicado: (2020)

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer
por: Ali, H R, et al.
Publicado: (2012)

Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
por: Fasanella, S, et al.
Publicado: (2011)

Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort
por: Fisher, G, et al.
Publicado: (2013)

Impact of cavity shaving on residual tumor rates in patients with primary invasive carcinoma and carcinoma in situ in breast conserving surgery
por: Fernández-Pacheco, Miriam, et al.
Publicado: (2022)

Ki-67 labeling index as a prognostic marker in advanced stomach cancer
por: Seo, Sang Hyuk, et al.
Publicado: (2019)

Prognostic and predictive value of Ki-67 in triple-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2016)

The prognostic and predictive potential of Ki-67 in triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2020)

Prognostic Value of Ki67 in Patients with Stage 1–2 Endometrial Cancer: Validation of the Cut-off Value of Ki67 as a Predictive Factor
por: Jiang, Peng, et al.
Publicado: (2020)

Ki-67 is a prognostic marker for hormone receptor positive tumors
por: Pérez-López, M. E., et al.
Publicado: (2016)

Gastrointestinal Stromal Tumor and Ki-67 as a Prognostic Indicator
por: Kadado, Kevin J, et al.
Publicado: (2022)

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies
por: Kitson, Sarah, et al.
Publicado: (2017)

Molecular subtyping of ependymoma and prognostic impact of Ki-67
por: Lim, Ka Young, et al.
Publicado: (2021)

Impact of the COVID-19 pandemic on reported cancer diagnoses in Bavaria, Germany
por: Voigtländer, Sven, et al.
Publicado: (2023)

HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women
por: Wege, Anja Kathrin, et al.
Publicado: (2018)

P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients
por: Pan, Yunbao, et al.
Publicado: (2017)

The Potential Value of Ki-67 in Prognostic Classification in Early Low-Risk Endometrial Cancer
por: Jia, Mingzhu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_23dmmvfdlfucj5g3vtlhui2mjf